drugset / Trial / NCT04338373

Effectiveness of 0.01% Atropine Sulfate Solution in Controlling of Myopia Progression in Children

NCT04338373

Phase 3 Unknown 70 enrolled The V.P. Vyhodcev Eye Hospital
NaSingle-groupOpen-labelTreatment

Summary

Increasing number of myopic children and significant complications of high myopia enhance the necessity of effective control strategy. Instillations of low-dose atropine have been shown to reduce myopia progression in Asian populations but its effect in non-Asian populations is still unclear. This open prospective study with historical control is designed to investigate if 0.01% atropine can reduce myopia progression in Russian children, taking into account a change of difference between manifest and cycloplegic refraction, as well as, myopia progression rate at the time of recruitment.

Timeline

Start
2020-02-17
Primary completion
2021-08
Completion
2021-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Atropine Other / unclassified 0.01 % Other

Indications